The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers

What Is Chronic Obstructive Pulmonary Disease Anyway?. Continua, Categories, Cut Points, and Moving beyond Spirometry

(2013) Stephen I. Rennard et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial

(2012) P. Nair et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?

(2012) N R Budha et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans

(2011) Aili L. Lazaar et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Dried Blood Spots as a Sample Collection Technique for the Determination of Pharmacokinetics in Clinical Studies: Considerations for the Validation of a Quantitative Bioanalytical Method

(2009) Neil Spooner et al.   ANALYTICAL CHEMISTRY

SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects

(2009) O. Holz et al.   EUROPEAN RESPIRATORY JOURNAL

Prevalence of gastroesophageal reflux disease in patients with asthma and chronic obstructive pulmonary disease

(2009) Serhat Bor et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Proton pump inhibitors: an update of their clinical use and pharmacokinetics

(2008) Shaojun Shi et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

CXCR2 antagonists for the treatment of pulmonary disease

(2008) R.W. Chapman et al.   PHARMACOLOGY & THERAPEUTICS